Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244907 · ClinicalTrials.gov registry record · Phase 1
Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women
A Phase 1 study, sponsored by Purdue University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00244907 is a Phase 1 study that has completed, run by Purdue University. The registered enrollment target is 23 participants.
The verdict
NCT00244907, a Phase 1 study, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.
Interventions
- DIETARY_SUPPLEMENT Genistein vs Risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244907
The ClinicalTrials.gov registry entry for NCT00244907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genistein vs Risedronate is the first listed.
NCT00244907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244907 about?
NCT00244907 is a clinical study titled "Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women". Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone ...
What is the current status of trial NCT00244907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00244907?
The interventions under investigation include: Genistein vs Risedronate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00244907?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.